Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E M H Schmitz

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Clinica Chimica Acta; International Journal of Clinical Chemistry|December 7, 2018
A value proposition for trough level-based anti-TNFα drug dosingV Scharnhorst, E M H Schmitz, D van de Kerkhof, et al.
Clinical Rheumatology|June 9, 2017
Therapeutic drug monitoring (TDM) as a tool in the switch from infliximab innovator to biosimilar in rheumatic patients: results of a 12-month observational prospective cohort studyE M H Schmitz, S Benoy-De Keuster, A J L Meier, et al.
Thrombosis Research|February 27, 2016
Determination of dabigatran and rivaroxaban by ultra-performance liquid chromatography-tandem mass spectrometry and coagulation assays after major orthopaedic surgeryM W M Schellings, K Boonen, E M H Schmitz, et al.
Alimentary Pharmacology & Therapeutics|December 6, 2017
Switching from infliximab innovator to biosimilar in patients with inflammatory bowel disease: a 12-month multicentre observational prospective cohort studyE M H Schmitz, P J Boekema, J W A Straathof, et al.
Journal of Thrombosis and Haemostasis : JTH|August 22, 2014
Determination of dabigatran, rivaroxaban and apixaban by ultra-performance liquid chromatography - tandem mass spectrometry (UPLC-MS/MS) and coagulation assays for therapy monitoring of novel direct oral anticoagulantsE M H Schmitz, K Boonen, D J A van den Heuvel, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Clinica Chimica Acta; International Journal of Clinical Chemistry|December 7, 2018
A value proposition for trough level-based anti-TNFα drug dosingV Scharnhorst, E M H Schmitz, D van de Kerkhof, et al.
Clinical Rheumatology|June 9, 2017
Therapeutic drug monitoring (TDM) as a tool in the switch from infliximab innovator to biosimilar in rheumatic patients: results of a 12-month observational prospective cohort studyE M H Schmitz, S Benoy-De Keuster, A J L Meier, et al.
Thrombosis Research|February 27, 2016
Determination of dabigatran and rivaroxaban by ultra-performance liquid chromatography-tandem mass spectrometry and coagulation assays after major orthopaedic surgeryM W M Schellings, K Boonen, E M H Schmitz, et al.
Alimentary Pharmacology & Therapeutics|December 6, 2017
Switching from infliximab innovator to biosimilar in patients with inflammatory bowel disease: a 12-month multicentre observational prospective cohort studyE M H Schmitz, P J Boekema, J W A Straathof, et al.
Journal of Thrombosis and Haemostasis : JTH|August 22, 2014
Determination of dabigatran, rivaroxaban and apixaban by ultra-performance liquid chromatography - tandem mass spectrometry (UPLC-MS/MS) and coagulation assays for therapy monitoring of novel direct oral anticoagulantsE M H Schmitz, K Boonen, D J A van den Heuvel, et al.
Pageof 1